Efficacy/safety of entrectinib in patients (pts) with ROS1-positive (ROS1 +) advanced/metastatic NSCLC from the Blood First Assay Screening Trial (BFAST)

Basit Öğe Kaydı
dc.authoridMok, Tony Shu Kam/0000-0002-8251-0551
dc.authorwosidDziadziuszko, Rafal/U-7036-2018
dc.authorwosidMok, Tony Shu Kam/B-2310-2019
dc.contributor.authorPeters, Solange
dc.contributor.authorGadgeel, Shirish M.
dc.contributor.authorMok, Tony S. K.
dc.contributor.authorNadal, Ernest
dc.contributor.authorKilickap, Saadettin
dc.contributor.authorPerol, Maurice
dc.contributor.authorCadranel, Jacques
dc.date.accessioned2024-05-19T14:51:36Z
dc.date.available2024-05-19T14:51:36Z
dc.date.issued2022
dc.departmentİstinye Üniversitesien_US
dc.descriptionAnnual Meeting of the American-Society-of-Clinical-Oncology (ASCO) -- JUN 03-07, 2022 -- ELECTR NETWORKen_US
dc.description.abstract[Abstract Not Available]en_US
dc.description.sponsorshipAmer Soc Clin Oncolen_US
dc.description.sponsorshipF. Hoffmann -La Roche Ltd.en_US
dc.description.sponsorshipF. Hoffmann -La Roche Ltd.en_US
dc.identifier.issn0732-183X
dc.identifier.issn1527-7755
dc.identifier.issue17en_US
dc.identifier.urihttps://hdl.handle.net/20.500.12713/5978
dc.identifier.volume40en_US
dc.identifier.wosWOS:000891791500036en_US
dc.identifier.wosqualityQ1en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.language.isoenen_US
dc.publisherLippincott Williams & Wilkinsen_US
dc.relation.ispartofJournal of Clinical Oncologyen_US
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.snmz20240519_kaen_US
dc.subject[No Keywords]en_US
dc.titleEfficacy/safety of entrectinib in patients (pts) with ROS1-positive (ROS1 +) advanced/metastatic NSCLC from the Blood First Assay Screening Trial (BFAST)en_US
dc.typeConference Objecten_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu